Forget Eli Lilly: These 2 Stocks Have More Upside

Eli Lilly's GLP-1 franchise is growing rapidly, with first-quarter 2026 sales of Mounjaro and Zepbound up 125% and 80%, respectively, but the stock trades at 34x earnings versus a 23x pharma average. Novo Nordisk is gaining traction with its GLP-1 pill, reporting 1.3 million prescriptions in the first quarter after launch and raising full-year 2026 guidance, while offering a 4% dividend yield. Pfizer remains behind in GLP-1s after dropping its candidate, but management is pivoting to new assets and pipeline programs, with a 6.5% yield supporting the turnaround case.

Analysis

The market is implicitly treating GLP-1 leadership as a winner-take-most platform, but the more important setup is that this is still a category with meaningful switching friction and pipeline optionality. That means relative share can move faster than absolute market growth: if Novo’s pill improves adherence and tolerability enough to reduce discontinuation, it can force Lilly to defend share with pricing or promotion, compressing near-term margins even if unit growth stays strong. The real second-order effect is on the rest of pharma: capital is likely to rotate toward companies with durable cash flow and late-stage optionality, while pure-play obesity exposure gets increasingly crowded and valuation-sensitive.

The underappreciated risk on Lilly is not demand, it is expectation decay. At a premium multiple, even a modest slowdown in sequential prescription growth or any hiccup in supply normalization could drive a sharp de-rating over the next 1-2 quarters, because the stock is already capitalizing several years of near-perfect execution. By contrast, Novo’s setup is more asymmetric: a lower starting multiple plus dividend support gives management room to surprise positively on guidance if the pill launch continues to scale and if formulary access broadens into 2H26.

Pfizer is more of a financing story than a near-term clinical one. Its equity can work if investors re-rate the company from 'lost GLP-1 participant' to 'pipeline plus dividend carry,' but the catalyst path is longer and more binary: oncology/migraine data, M&A integration, and patent cliff stabilization over 6-18 months. The key contrarian takeaway is that the market may be over-penalizing Pfizer’s failed first attempt while underestimating the value of multiple shots on goal, especially in a risk-off tape where 6%+ cash yield becomes meaningful.

The broader positioning signal is crowded long Lilly, under-owned Novo, and extreme skepticism on Pfizer. That creates a cleaner relative-value expression than outright directional longs: the next leg of outperformance is likely to come from multiple expansion in the laggards rather than further rerating of the leader. If the GLP-1 trade broadens from growth narrative to cash-yield-and-guidance narrative, capital should rotate down the quality ladder.

Key Decisions for Investors

• Initiate a pair trade: long NVO / short LLY over the next 1-3 months. The thesis is not that Lilly's business weakens, but that Novo has more rerating room if pill uptake keeps beating expectations; target 10-15% relative outperformance with defined valuation gap compression risk.
• Consider buying PFE Jan-2027 call spreads or a staged common-stock entry for income-plus-recovery exposure. Use time, not precision, as the edge: the catalyst stack is 6-18 months out, but the 6.5% dividend limits downside if the turnaround takes longer than expected.
• Trim or hedge existing LLY longs into strength, especially ahead of quarterly prints. At current multiples, a 1-2 quarter pause in prescription acceleration could trigger a 15-20% de-rating even without fundamental deterioration.
• For conservative income accounts, accumulate NVO on pullbacks with a 12-month horizon. The combination of visible growth, a 4% yield, and reasonable payout coverage creates a better risk-adjusted profile than chasing LLY at premium valuation.
• Avoid naked shorting LLY; use defined-risk put spreads if expressing a valuation mean-reversion view. The stock can stay expensive longer than expected, but the asymmetry improves if guidance or supply commentary disappoints.